Abstract:Background: Cervical carcinoma is the second most common neoplasm in women worldwide and is the most frequent

No abstract

Background: Cytomegalovirus (CMV) infection is a matter for concern among blood bank professionals and blood transfusion recipient, especially in cases of transfusion to neonates and immunocompromised patients. Objective: The aim of the study was to investigate the seroprevalence of cytomegalovirus with the purpose of determining routine CMV screening for donors. Method: A descriptive cross sectional study was carried out in the Department of Transfusion Medicine in Bangabandhu Sheikh Mujib Medical University from January 2017 to December 2017. A total of 150 blood donors were selected by convenient sampling technique. Result: The seroprevalence of cytomegalovirus is 91% for IgG and 4% for IgM. Association was found in between IgG and age,sex.In case of age anti-CMV-IgG,c2= 26.5, t = 9.49; c2> t (Association Exists),for sex anti-CMV-IgG: df = 1, CI = 95%, c2= 17.8, t = 3.84; c2> t (Association Exists)Anti-CMV-IgM: df = 1, CI = 95%, c2= 10.7, t = 3.84; c2> t (Association Exist). This study was undertaken to find out seroprevalence of Cytomegalovirus among blood donors in the department of transfusion medicine. The incidence of cytomegalovirus is 91.3% for IgG and 4% for IgM. Most of the IgG positive subjects were in 38-47 years and for IgM were in 28-37 years. It was observed that seroprevalence of CMV was more in female (94.9% in case of IgG& 6.8% in IgM). It was observed that the highest prevalence of IgG was 3out of 3 (100%)in illiterate and that of IgM was 1 out of 3(33.33%) in illiterate level of education. In conclusion it was found that seroprevalence of cytomegalovirus was 91.3% for IgG and 4% for IgM. Association was found in between IgG & age, sex. Conclusion: Prospective blood donors should be screened for CMV most especially for immunocompromised recipients. Leucoreduced blood products from CMV seronegative donors should be given to preterm neonates, infants as this will prevent transfusion associated perinatal CMV disease. There should be more campaign and awareness on provision of voluntary blood donation for CMV negative blood. Program should be made to create awareness in the community on the significant impact of CMV infection on health.

The Rhesus blood group system is one of the most polymorphic and highly immunogenic systems in humans. Because of its high and strong immunogenicity Rh D antigen testing is mandatory before issuing a compatible blood. There are five major antigens i.e. DCEce in the Rhesus (Rh) blood group system. On the other hand from the immunogenicity point of view Kell antigen is next to the Rh system. Both of them may cause severe hemolytic transfusion reaction and hemolytic disease of fetus and new born. Exposure of Rhesus negative individuals to Rhesus positive blood through transfusion or pregnancy is most likely to stimulate production of Rhesus antibodies. These antibodies may cause Hemolytic Disease of Fetus and Newborn (HDFN) and Delayed Hemolytic Transfusion Reaction (DHTR). Like Rhesus antibodies, Kell antibodies may also cause HDFN and DHTR. So far we know, there is not enough study regarding antigens C, c, E & e of Rh or K, k antigen of Kell blood group system regarding these antigens in the donors in Bangladesh, thereby exposing transfused patients to these antigens negative patients. To determine the phenotype prevalence of the Rh and Kell blood group systems in the blood donors in Bangladesh, a descriptive cross sectional study was done in the laboratory of Department of Transfusion Medicine, Bangabandhu Sheikh Mujib Medical University, during the period of 1st January 2020 to 31 December 2020. Rhesus Phenotype CCDee is highest (48.4%) & CCDEe & ccDEE both are lowest (0.4%). Most probable Rhesus Genotype CDe/CDe (R1R1) is highest (48.4%) and CDe/CDE (R1Rz) & cDE/cDE (R2R2) both are lowest (0.4%). Kell Genotype kk is highest (99.2%) and Kk is lowest (0.8%). BSMMU J 2021; 14(3): 38-42

Haemophilia is one of the most common causes of inherited bleeding disorder resulting from deficiency of coagulation factor VIII or factor IX. Ideally, replacement should be done with factor concentrate. Due to economic constraints associated with its procurement, bleeding episodes are regularly dealt with Fresh Frozen Plasma (FFP) or cryoprecipitate in low-resource countries. This study was carried out to compare the utilization profile and clinical characteristics of haemophilia patients receiving FFP and cryoprecipitate for replacing clotting factor deficiency. This cross-sectional comparative study was conducted in the day care unit of the Department of Transfusion Medicine of Bangabandhu Sheikh Mujib Medical University between 2 groups of haemophilia patients receiving either cryoprecipitate or FFP for treatment. Out of the total 100 haemophilia patients, 50 were treated with cryoprecipitate and 50 with FFP. In FFP group, the majority of patients (48% in cryoprecipitate group and 36% in FFP group) were in the age group of more than 5 to 10 years followed by 11 to 15 years age (24% versus 30%) with a mean SD of age in cryoprecipitate group and FFP group being 11.78±5.61 and 13.42±6.12 years, respectively. About 33 (66.0%) had a history of bleeding following trauma and 32 (64.0%) had a history of spontaneous bleeding among the patients in cryoprecipitate group as a cause of swelling/bleeding and in FFP group, 23 (46.0%) had history of spontaneous bleeding followed by 23 (34.0%) with history of bleeding following trauma. Regarding the type of bleeding, oral bleeding was most common, followed by soft tissue bleeding in both group (40.0% versus 38.0%). Presence of ecchymosis in both groups was statistically significant. The difference in type of haemophilia between the two groups was statistically significant (p<0.001) with a prevalence of haemophilia A of about 88%. The life expectancy of haemophilia patients is increasing dramatically day by day with successful and effective treatment with the appropriate plasma component. Cryoprecipitate is better than FFP as there is less chance of volume overload minimizing leucocyte induced non-haemolytic febrile transfusion reaction and rapid correction of coagulation factor.